Hennion & Walsh Asset Management Inc. Lowers Position in Kiniksa Pharmaceuticals International, plc $KNSA

Hennion & Walsh Asset Management Inc. decreased its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 35.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 79,200 shares of the company’s stock after selling 42,619 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Kiniksa Pharmaceuticals International were worth $3,267,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of KNSA. SG Americas Securities LLC increased its holdings in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after acquiring an additional 402,078 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its position in shares of Kiniksa Pharmaceuticals International by 16.2% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 14,792 shares of the company’s stock valued at $610,000 after purchasing an additional 2,063 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after purchasing an additional 771 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Kiniksa Pharmaceuticals International by 42.3% in the third quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock worth $7,473,000 after purchasing an additional 57,174 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter worth about $1,180,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Trading Up 5.4%

Shares of NASDAQ:KNSA opened at $48.15 on Wednesday. The company has a market cap of $3.69 billion, a price-to-earnings ratio of 65.07 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.25 and a 12 month high of $49.12. The company has a 50-day moving average price of $45.15 and a 200 day moving average price of $41.67.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. During the same period in the previous year, the firm earned ($0.12) earnings per share. The company’s revenue was up 65.0% compared to the same quarter last year. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the sale, the chief financial officer owned 12,086 shares in the company, valued at approximately $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Barry D. Quart sold 12,528 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total value of $567,142.56. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at approximately $567,957.42. This represents a 49.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 48,605 shares of company stock valued at $2,122,646. Company insiders own 53.48% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective on the stock. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $55.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.